Antioxidant and NMDA Receptor Blocker Wins Anoxic Brain Damage of KorEa OHCA Patients

PHASE2UnknownINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

November 29, 2018

Primary Completion Date

May 31, 2021

Study Completion Date

May 31, 2021

Conditions
Cardiac Arrest
Interventions
DRUG

Neu2000KWL High-dose group

1st infusion of 1500mg in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of 750 mg at intervals of 12 hours(Total drug dosage is 5250mg.)

DRUG

Neu2000KWL Low-dose group

1st infusion of 750mg in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of 500 mg at intervals of 12 hours (Total drug dosage is 3250mg.)

DRUG

Placebo

1st infusion of the same volume of saline in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of the same volume of saline at intervals of 12 hours

Trial Locations (6)

14584

Soonchunhyang University Bucheon Hospital, Bucheon-si

41944

Kyungpook National University Hospital, Daegu

49241

Pusan National University Hospital, Busan

61469

Chonnam National University Hospital, Gwangju

06273

Gangnam Severance Hospital, Seoul

06351

Samsung Medical Center, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Samsung Medical Center

OTHER

collaborator

Chonnam National University Hospital

OTHER

collaborator

Gangnam Severance Hospital

OTHER

collaborator

Kyungpook National University Hospital

OTHER

collaborator

Pusan National University Hospital

OTHER

collaborator

Soonchunhyang University Hospital

OTHER

lead

GNT Pharma

INDUSTRY